Takeda Pharmaceutical Company Limited announced new Phase 3 results showing zasocitinib's superior efficacy over deucravacitinib, with higher rates of complete skin clearance observed as early as week 8.
More than 2.5 times as many patients treated with zasocitinib achieved complete skin clearance (PASI 100) at week 16 compared to deucravacitinib, according to data presented during the EADV Congress 2026.
Additional analyses from pivotal LATITUDE studies showed durable skin clearance and rapid improvements in patient-reported itch and quality of life. Zasocitinib also demonstrated superiority over apremilast for treating moderate-to-severe plaque psoriasis.
Takeda plans to submit applications to global regulatory authorities, aiming to bring zasocitinib to people with psoriasis worldwide, while it continues evaluating the drug in other inflammatory conditions.
SK Pharmteco · Oct 1, 2026 08:56 KST
Galderma · Sep 30, 2026 17:31 KST
ProductLife Group · Sep 30, 2026 08:39 KST
Daewoong Pharmaceutical · Sep 29, 2026 15:16 KST
AI illustrationCamp Therapeutics · Sep 28, 2026 11:50 KST
Daewoong Pharmaceutical · Sep 28, 2026 11:42 KST
